FindTrial
Sign In

comparison of two different treatment methods for migraine headache not relived by usual medical treatment.

Randomized, observer-blind study comparing effectiveness of pulsed radiofrequency ablation of greater nerve with greater occipital nerve injection for refractory migraine with occipital neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015208
Enrollment
45
Registered
2018-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G431- Migraine with aura

Interventions

Intervention1: GROUP 1: Patients will receive USG-guided greater occipital nerve block with bupivacaine 2.5 ml. Intervention2: GROUP 2: Patient will receive USG-guided PRF of greater occipital nerve f

Sponsors

Post graduation institute of medical education and research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 International classification of headache disorders second edition (ICHD-2) defined chronic migraine patients. 2 Patients of refractory migraine with occipital neuralgia. Refractory migraine are the patients who fail to respond adequately to preventive medication with established efficacy, alone or in combination, including more than 2 of 4 drugs classes(beta blockers, anticonvulsant, tricyclic and calcium channel blockers).

Exclusion criteria

Exclusion criteria: 1 Polyneuropathies irrespective of the etiology (diabetic, alcoholic, etc.). 2 Intracranial pathologic lesion. 3 Central neuropathic pain states. 4 Psychiatric comorbidity afflicting pain perception. 5 Previous interventions for treatment of the occipital neuralgia (ON). 6 Neck surgery. 7 Coagulation disorders. 8 Infection at the infiltration sites. 9 Cervical spinal cord injury. 10 Intervertebral disc herniation at level C1-2 or C2-3. 11 Neoplastic disease causing ON. 12 Individuals with continuous headache or using maintenance opioid medication. 13 Known hypersensitivity or allergic reaction to local anesthetics. 14 Implanted cardiac pacemaker or defibrillator that could not be disabled, 15 Previous PRF treatment of any nerve 16 Pregnancy

Design outcomes

Primary

MeasureTime frame
To assess reduction in the frequency of days with moderate or severe migraine (NRS3).Timepoint: 1 month,2 month and 3 months after the procedure—

Secondary

MeasureTime frame
To measures the reduction in mean frequency of all migraine headache days, mean number of hours with moderate or severe migraine headache, the mean number of days with acute medication.Timepoint: 1 month,2 month and 3 month after the procedure—

Countries

India

Contacts

Public ContactParveen kumar negi

post graduate institute of medical education and reasearch, Chandigarh

bhartineerja@yahoo.com7087009527

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026